论文部分内容阅读
目的研究阿托伐他汀对冠状动脉造影术后冠心病患者的肾功能保护作用。方法 2009年1月～2011年6月期间收集某院冠心病行冠状动脉造影术患者124例,随机分为观察组与对照组2组,观察组术前予阿托伐他汀强化治疗,对照组予常规治疗,比较2组的超敏C反应蛋白。对各指标率的变化采用组间t检验,计数资料采用组间χ2检验。结果对照组冠状动脉造影术后24h、48h冠心病患者Cys C、GFR与术前相比较差异有统计学意义,P﹤0.05;观察组冠状动脉造影术后24h、48h冠心病患者血清Cys C、GFR与对照组分别相比较,差异有统计学意义,P﹤0.05。对照组冠状动脉造影术后24h、48h冠心病患者血清hs-CRP、尿mALB与术前相比较出现不同程度的升高,差异有统计学意义,P﹤0.05;观察组冠状动脉造影术后24h、48h冠心病患者血清hs-CRP、尿mALB与对照组分别相比较,差异有统计学意义,P﹤0.05。结论阿托伐他汀早期干预对冠心病患者行冠状动脉造影术后的肾功能具有保护作用,其机制可能与降低对比剂引起的炎症反应有关。
Objective To study the renal protective effect of atorvastatin on patients with coronary heart disease after coronary angiography. Methods From January 2009 to June 2011, 124 patients with coronary heart disease underwent coronary angiography in a hospital were randomly divided into two groups: observation group and control group. The observation group was treated with atorvastatin pretreatment and the control group To conventional treatment, the two groups of high-sensitivity C-reactive protein. Changes in the rate of each indicator using t test between groups, count data using the χ2 test between groups. Results The Cys C and GFR in coronary heart disease patients at 24 and 48 hours after coronary angiography were significantly different from those before surgery (P <0.05). The levels of serum Cys C and Cys in patients with coronary heart disease at 24 and 48 hours after coronary angiography GFR and control group respectively, the difference was statistically significant, P <0.05. The levels of serum hs-CRP and urine mALB in patients with coronary heart disease at 24h and 48h after coronary angiography were significantly increased compared with those before operation, the difference was statistically significant (P <0.05). In the control group, 24h The serum hs-CRP and urine mALB in patients with coronary heart disease at 48h were significantly different from those in control group (P <0.05). Conclusion Early intervention with atorvastatin can protect renal function after coronary angiography in patients with coronary heart disease. The mechanism of atorvastatin may be related to reducing the inflammatory reaction induced by contrast agent.